Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenblatt, A.
Right arrow Articles by Ross, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenblatt, A.
Right arrow Articles by Ross, C. A.
Related Collections
Right arrow Huntington's disease
Right arrow Prognosis
Right arrow Trinucleotide repeat diseases
NEUROLOGY 2006;66:1016-1020
© 2006 American Academy of Neurology

The association of CAG repeat length with clinical progression in Huntington disease

A. Rosenblatt, MD, K. -Y. Liang, PhD, H. Zhou, MS, M. H. Abbott, MPH, RN, L. M. Gourley, MA, R. L. Margolis, MD, J. Brandt, PhD and C. A. Ross, MD, PhD

From the Department of Psychiatry (A.R., M.H.A.,L.M.G., R.L.M., J.B., C.A.R.), Johns Hopkins University School of Medicine, and Department of Biostatistics (K.-Y.L., H.Z.), School of Public Health, Johns Hopkins University, Baltimore, MD.

Address correspondence and reprint requests to Dr. A. Rosenblatt, Johns Hopkins Hospital, Meyer 2-181, 600 N. Wolfe St., Baltimore, MD 21287-7281; e-mail: arosenba{at}jhmi.edu

Objective: To determine whether the rate of clinical progression in Huntington disease (HD) is influenced by the size of the CAG expansion.

Methods: The dataset consisted of 3,402 examinations of 512 subjects seen through the Baltimore Huntington's Disease Center. Subjects were seen for a mean of 6.64 visits, with mean follow-up of 6.74 years. Subjects were administered the Quantified Neurological Examination, with its subsets the Motor Impairment and Chorea Scores, the Mini-Mental State Examination, and the HD Activities of Daily Living (ADL) Scale.

Results: In an analysis based on the Random Effects Model, CAG length was significantly associated with the rate of progression of all measures except chorea and ADL. There was a significant interaction term between CAG length and disease duration for all measures except chorea. Further graphical exploration of the data supported these linear models and suggested that subjects at the low end of the expanded CAG repeat range may experience a more benign late course.

Conclusions: CAG repeat length has a small effect on rate of progression that may be clinically important over time. Individuals with the shortest expansions appear to have the best prognosis. These effects of the CAG length may be relevant in the analysis of clinical trials.


Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 11 issue to find the title link for this article.

Supported by the National Institute of Neurological Disorders and Stroke and the Huntington's Disease Society of America.

Disclosure: Dr. Rosenblatt has given expert testimony related to the subject of this article.

Received June 3, 2005. Accepted in final form December 16, 2005.




This article has been cited by other articles:


Home page
NeurologyHome page
N. A. Aziz, J.M.M. van der Burg, G. B. Landwehrmeyer, P. Brundin, T. Stijnen, EHDI Study Group, and R. A.C. Roos
Weight loss in Huntington disease increases with higher CAG repeat number
Neurology, November 4, 2008; 71(19): 1506 - 1513.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
J. L. Waugh, V. S. Miller, R. S. Chudnow, and M. M. Dowling
Juvenile Huntington Disease Exacerbated by Methylphenidate: Case Report
J Child Neurol, July 1, 2008; 23(7): 807 - 809.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
H H Ruocco, L Bonilha, L M Li, I Lopes-Cendes, and F Cendes
Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat
J. Neurol. Neurosurg. Psychiatry, February 1, 2008; 79(2): 130 - 135.
[Abstract] [Full Text] [PDF]


Home page
JWatch NeurologyHome page
Does CAG Repeat Length Affect Clinical Progression in Huntington Disease?
Journal Watch Neurology, June 8, 2006; 2006(608): 9 - 9.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.